Should Capecitabine Replace Infusional Fluorouracil and Leucovorin When Combined With Oxaliplatin in Metastatic Colorectal Cancer?-Reference-Cited by-同舟云学术

Should Capecitabine Replace Infusional Fluorouracil and Leucovorin When Combined With Oxaliplatin in Metastatic Colorectal Cancer?

Published:2007-09-20 Issue:27 Volume:25 Page:4165-4167
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Mayer Robert J.¹

Affiliation:

1. Dana-Farber Cancer Institute, Boston, MA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2007.11.6582

Reference25 articles.

1. Systemic Therapy for Colorectal Cancer

2. A double-blind comparison of intensive course 5-fluorouracil by oral vs. intravenous route in the treatment of colorectal carcinoma

3. Zhang ZG, Harstrick A, Rustum YM: Modulation of fluoropyrimidines: Role of dose and schedule of leucovorin administration. Semin Oncol 19:10,1992-15, (suppl 3)

4. Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study

5. Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mucinous ovarian cancer: A therapeutic review;Critical Reviews in Oncology/Hematology;2016-06

2. XELOXvs.FOLFOX in metastatic colorectal cancer: An updated meta-analysis;Cancer Investigation;2016-02-07

3. Effect of Neoadjuvant Chemoradiotherapy with Capecitabine versus Fluorouracil for Locally Advanced Rectal Cancer: A Meta-Analysis;Gastroenterology Research and Practice;2016

4. Race and Insurance Differences in the Receipt of Adjuvant Chemotherapy Among Patients With Stage III Colon Cancer;Journal of Clinical Oncology;2015-08-10

5. Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer;Cancer Chemotherapy and Pharmacology;2015-03-15